SCHEMBL297622

SCHEMBL297622

O=C(O)c1ccccc1-c1ncc[nH]1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK1A1 P48729 1/20 0.73
TYRO3 Q06418 1/20 0.73
DYRK1B Q9Y463 1/20 0.73
KDM4E B2RXH2 5/20 0.54
RAB9A P51151 1/20 0.54
MTOR P42345 1/20 0.52
ADK P55263 1/20 0.52
NISCH Q9Y2I1 1/20 0.52
ALDH1A1 P00352 3/20 0.51
POLB P06746 1/20 0.48
HCRTR1 O43613 2/20 0.46
HCRTR2 O43614 2/20 0.46
KMT2A Q03164 1/20 0.44
ALOX15 P16050 2/20 0.43
IDO1 P14902 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
ADRA2A P08913 1/20 0.43
ADRA2B P18089 1/20 0.43
ADRA2C P18825 1/20 0.43
MYC P01106 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30965100 1.00 CSNK1A1 (0.73) CSNK1A1TYRO3DYRK1BKDM4ERAB9A
Hydrochloric Acid SCHEMBL5854599 0.98 CSNK1A1 (0.71) CSNK1A1TYRO3DYRK1BKDM4ERAB9A
SCHEMBL10714674 0.88 CSNK1A1 (0.76) CSNK1A1TYRO3DYRK1BKDM4ERAB9A
SCHEMBL28348460 0.87 CSNK1A1 (0.60) CSNK1A1TYRO3DYRK1BKDM4ERAB9A
SCHEMBL6005082 0.85 CSNK1A1 (0.68) CSNK1A1TYRO3DYRK1BKDM4EMTOR
SCHEMBL6825869 0.85 CSNK1A1 (1.00) CSNK1A1TYRO3DYRK1BKDM4ERAB9A
SCHEMBL15478263 0.85 CSNK1A1 (0.71) CSNK1A1TYRO3DYRK1BKDM4EMTOR
SCHEMBL11566235 0.85 CSNK1A1 (0.71) CSNK1A1TYRO3DYRK1BKDM4ERAB9A
SCHEMBL27401060 0.84 CSNK1A1 (0.57) CSNK1A1TYRO3DYRK1BKDM4ERAB9A
Water SCHEMBL30473073 0.83 CSNK1A1 (0.97) CSNK1A1TYRO3DYRK1BKDM4ERAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101863894-B Tanshinone II A derivative and preparation method and application thereof UNIV GUANGDONG PHARM 2012-07-18 CN claimed
CN-101863894-A Tanshinone II A derivative and preparation method and application thereof GUANGDONG PHARMACEUTICAL UNIVERSITY 2010-10-20 CN claimed
CN-101735217-A Application of imidazole [4,5-f][1,10] phenanthroline and derivative thereof to preparation of antineoplastic drug UNIV GUANGDONG PHARM 2010-06-16 CN claimed
EP-3693434-B1 ADHESIVE COMPOSITION FOR SEMICONDUCTOR CIRCUIT CONNECTION AND ADHESIVE FILM INCLUDING THE SAME LG CHEMICAL LTD (KR) 2025-10-08 EP disclosed
US-12378254-B2 Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2025-08-05 US disclosed
US-20240109901-A1 DISUBSTITUTED OCTAHYDROPYRROLO[3,4-C]PYRROLES AS OREXIN RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-04-04 US disclosed
US-11834415-B2 Adhesive composition for semiconductor circuit connection and adhesive film including the same LG CHEM, LTD. (KR) 2023-12-05 US disclosed
US-11667644-B2 Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2023-06-06 US disclosed
CN-114262443-B Lanthanide metal organic framework material, and synthesis method and application thereof 中国科学院福建物质结构研究所 2022-10-14 CN disclosed
CN-114262443-A Lanthanide metal organic framework material, and synthesis method and application thereof 中国科学院福建物质结构研究所 2022-04-01 CN disclosed
US-RE48841-E1 Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2021-12-07 US disclosed
CN-101139346-A Benzimidazole-derivatives as factor Xa inhibitors SANOFI AVENTIS DEUTSCHLAND (DE) 2008-03-12 CN disclosed
US-20050038067-A1 Asymmetric benzimidazoles and related compounds as potassium channel modulators ICAGEN, INC. (US) 2005-02-17 US disclosed
WO-2005002503-A2 ASYMMETRIC BENZIMIDAZOLES AND RELATED COMPOUNDS AS POTASSIUM CHANNEL MODULATORS ICAGEN, INC. (US) 2005-01-13 WO disclosed
EP-0169164-B1 IMIDAZOLONECARBONYLARYLIMIDAZOLES; METHOD OF MANUFACTURE, METHOD OF USE AND COMPOSITIONS USEFUL THEREOF SCHERING AKTIENGESELLSCHAFT (DE) 1990-01-31 EP disclosed
US-4874747-A DERMATOLOGY CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES (CIRD) (FR) 1989-10-17 US disclosed
US-4777250-A LOW MOLECULAR WEIGHT; STABLE NORTHWESTERN UNIVERSITY (US) 1988-10-11 US disclosed
US-4709043-A Process for the preparation of imidazolonecarbonylarylimidazoles SCHERING A.G. (DE) 1987-11-24 US disclosed
EP-0169164-A1 Imidazolonecarbonylarylimidazoles; method of manufacture, method of use and compositions useful thereof SCHERING AKTIENGESELLSCHAFT (DE) 1986-01-22 EP disclosed
US-4556665-A Cardiotonic 1,3-dihydro-4-[[(imidazol-1-yl)aryl]carbonyl]imidazol-2-ones SCHERING A.G. (DE) 1985-12-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109901-A1 DISUBSTITUTED OCTAHYDROPYRROLO[3,4-C]PYRROLES AS OREXIN RECEPTOR MODULATORS HCRTR2, HCRTR1, OXTR CSNK1A1 3832/4885TYRO3 2113/4885DYRK1B 2529/4885
US-12378254-B2 Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators HCRTR2, HCRTR1, OXTR CSNK1A1 3832/4885TYRO3 2113/4885DYRK1B 2529/4885
US-20050038067-A1 Asymmetric benzimidazoles and related compounds as potassium channel modulators KCNJ2, KCNJ1, KCNJ11 CSNK1A1 2237/4885TYRO3 3998/4885DYRK1B 779/4885
US-11834415-B2 Adhesive composition for semiconductor circuit connection and adhesive film including the same ASH2L, CDH1, AS3MT CSNK1A1 4026/4885TYRO3 1113/4885DYRK1B 2356/4885
US-11667644-B2 Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators HCRTR2, HCRTR1, OXTR CSNK1A1 3832/4885TYRO3 2113/4885DYRK1B 2529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.